_id
690f3af0ccc777a4e85d1988
Ticker
CALA
Name
Calithera Biosciences Inc
Exchange
PINK
Address
343 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Country
USA
Sector
Financial Services
Industry
Shell Companies
Currency
USD
Website
https://www.calithera.com
Description
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Last Close
0.0003
Volume
225
Current Price
0.0003
Change
0
Last Updated
2025-11-29T11:07:35.244Z
Image
-
Ipo Date
2014-10-02T00:00:00.000Z
Market Cap
974
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
3
Target Price
5
Strong Buy
0
Buy
0
Hold
1
Sell
0
Strong Sell
0
Current Quarter
2022-12-31
Revenue
0
Cost Of Revenue
357000
Gross Profit
-357000
Operating Expenses
6989000
Operating Income
-7346000
Interest Expense
21060000
Pretax Income
-6936000
Net Income
-6936000
Eps
-1.4248151191454397
Dividends Per Share
-
Shares Outstanding
4872497
Income Tax Expense
-21060000
EBITDA
-7281000
Operating Margin
-
Total Other Income Expense Net
410000
Cash
25451000
Short Term Investments
-
Receivables
-
Inventories
-
Total Current Assets
26624000
Property Plant Equipment
1782000
Total Assets
28676000
Payables
732000
Short Term Debt
1530000
Long Term Debt
-
Total Liabilities
8284000
Equity
20392000
Depreciation
65000
Change In Working Capital
-2786000
Cash From Operations
-8598000
Capital Expenditures
23000
Cash From Investing
-23000
Cash From Financing
4000
Net Change In Cash
-8617000
PE
-
PB
0.00007161632012553943
ROE
-34.013338564142806
ROA
-24.187473845724647
FCF
-8621000
Fcf Percent
-
Piotroski FScore
0
Health Score
41
Deep Value Investing Score
7
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
2.5
Net Net Investing Score
8
Quality Investing Score
3
Value Investing Score
5.5
Quarters > 0 > quarter
2022-12-31
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
357000
Quarters > 0 > income Statement > gross Profit
-357000
Quarters > 0 > income Statement > operating Expenses
6989000
Quarters > 0 > income Statement > operating Income
-7346000
Quarters > 0 > income Statement > interest Expense
21060000
Quarters > 0 > income Statement > pretax Income
-6936000
Quarters > 0 > income Statement > net Income
-6936000
Quarters > 0 > income Statement > eps
-1.4248151191454397
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
4868000
Quarters > 0 > income Statement > income Tax Expense
-21060000
Quarters > 0 > income Statement > EBITDA
-7281000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
410000
Quarters > 0 > balance Sheet > cash
25451000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
26624000
Quarters > 0 > balance Sheet > property Plant Equipment
1782000
Quarters > 0 > balance Sheet > total Assets
28676000
Quarters > 0 > balance Sheet > payables
732000
Quarters > 0 > balance Sheet > short Term Debt
1530000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
8284000
Quarters > 0 > balance Sheet > equity
20392000
Quarters > 0 > cash Flow > net Income
-6936000
Quarters > 0 > cash Flow > depreciation
65000
Quarters > 0 > cash Flow > change In Working Capital
-2786000
Quarters > 0 > cash Flow > cash From Operations
-8598000
Quarters > 0 > cash Flow > capital Expenditures
23000
Quarters > 0 > cash Flow > cash From Investing
-23000
Quarters > 0 > cash Flow > cash From Financing
4000
Quarters > 0 > cash Flow > net Change In Cash
-8617000
Quarters > 0 > ratios > PE
-1.4248151191454397
Quarters > 0 > ratios > PB
0.00007161632012553943
Quarters > 0 > ratios > ROE
-34.013338564142806
Quarters > 0 > ratios > ROA
-24.187473845724647
Quarters > 0 > ratios > FCF
-8621000
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
41
Quarters > 1 > quarter
2022-09-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
348000
Quarters > 1 > income Statement > gross Profit
-348000
Quarters > 1 > income Statement > operating Expenses
9526000
Quarters > 1 > income Statement > operating Income
-9526000
Quarters > 1 > income Statement > interest Expense
177000
Quarters > 1 > income Statement > pretax Income
-9802000
Quarters > 1 > income Statement > net Income
-9802000
Quarters > 1 > income Statement > eps
-2.0147995889003085
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
4865000
Quarters > 1 > income Statement > income Tax Expense
276000
Quarters > 1 > income Statement > EBITDA
-9464000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-276000
Quarters > 1 > balance Sheet > cash
34068000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
34697000
Quarters > 1 > balance Sheet > property Plant Equipment
2116000
Quarters > 1 > balance Sheet > total Assets
37083000
Quarters > 1 > balance Sheet > payables
1012000
Quarters > 1 > balance Sheet > short Term Debt
1490000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
10695000
Quarters > 1 > balance Sheet > equity
26388000
Quarters > 1 > cash Flow > net Income
-9802000
Quarters > 1 > cash Flow > depreciation
62000
Quarters > 1 > cash Flow > change In Working Capital
326000
Quarters > 1 > cash Flow > cash From Operations
-7736000
Quarters > 1 > cash Flow > capital Expenditures
110000
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
15000
Quarters > 1 > cash Flow > net Change In Cash
-7721000
Quarters > 1 > ratios > PE
-2.0147995889003085
Quarters > 1 > ratios > PB
0.00005530923146884947
Quarters > 1 > ratios > ROE
-37.145672275276645
Quarters > 1 > ratios > ROA
-26.432597146940644
Quarters > 1 > ratios > FCF
-7846000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
42
Quarters > 2 > quarter
2022-06-30
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
11376000
Quarters > 2 > income Statement > operating Income
-11376000
Quarters > 2 > income Statement > interest Expense
68000
Quarters > 2 > income Statement > pretax Income
-9077000
Quarters > 2 > income Statement > net Income
10220000
Quarters > 2 > income Statement > eps
1.7932970696613442
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
5699000
Quarters > 2 > income Statement > income Tax Expense
-19297000
Quarters > 2 > income Statement > EBITDA
-11376000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
2299000
Quarters > 2 > balance Sheet > cash
41789000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
42824000
Quarters > 2 > balance Sheet > property Plant Equipment
2464000
Quarters > 2 > balance Sheet > total Assets
45558000
Quarters > 2 > balance Sheet > payables
990000
Quarters > 2 > balance Sheet > short Term Debt
1451000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
10307000
Quarters > 2 > balance Sheet > equity
35251000
Quarters > 2 > cash Flow > net Income
-9077000
Quarters > 2 > cash Flow > depreciation
64000
Quarters > 2 > cash Flow > change In Working Capital
-1274000
Quarters > 2 > cash Flow > cash From Operations
-11264000
Quarters > 2 > cash Flow > capital Expenditures
110000
Quarters > 2 > cash Flow > cash From Investing
-110000
Quarters > 2 > cash Flow > cash From Financing
8499000
Quarters > 2 > cash Flow > net Change In Cash
-2875000
Quarters > 2 > ratios > PE
1.7932970696613442
Quarters > 2 > ratios > PB
0.00004850075175172335
Quarters > 2 > ratios > ROE
28.992085330912598
Quarters > 2 > ratios > ROA
22.432942622590982
Quarters > 2 > ratios > FCF
-11374000
Quarters > 2 > ratios > Piotroski FScore
2
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
81
Quarters > 3 > quarter
2022-03-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
13826000
Quarters > 3 > income Statement > operating Income
-13826000
Quarters > 3 > income Statement > interest Expense
9000
Quarters > 3 > income Statement > pretax Income
-13835000
Quarters > 3 > income Statement > net Income
-13844000
Quarters > 3 > income Statement > eps
-3.528572156802773
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
3923400
Quarters > 3 > income Statement > income Tax Expense
9000
Quarters > 3 > income Statement > EBITDA
-13762000
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-9000
Quarters > 3 > balance Sheet > cash
44664000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
127000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
47269000
Quarters > 3 > balance Sheet > property Plant Equipment
2697000
Quarters > 3 > balance Sheet > total Assets
50236000
Quarters > 3 > balance Sheet > payables
2124000
Quarters > 3 > balance Sheet > short Term Debt
1412000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
53372000
Quarters > 3 > balance Sheet > equity
-3136000
Quarters > 3 > cash Flow > net Income
-13835000
Quarters > 3 > cash Flow > depreciation
64000
Quarters > 3 > cash Flow > change In Working Capital
-3692000
Quarters > 3 > cash Flow > cash From Operations
-16010000
Quarters > 3 > cash Flow > capital Expenditures
110000
Quarters > 3 > cash Flow > cash From Investing
-110000
Quarters > 3 > cash Flow > cash From Financing
1137000
Quarters > 3 > cash Flow > net Change In Cash
-14873000
Quarters > 3 > ratios > PE
-3.528572156802773
Quarters > 3 > ratios > PB
-0.00037532525510204076
Quarters > 3 > ratios > ROE
441.4540816326531
Quarters > 3 > ratios > ROA
-27.557926586511666
Quarters > 3 > ratios > FCF
-16120000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
38
Valuation > metrics > PE
-1.4248151191454397
Valuation > metrics > PB
0.00007161632012553943
Valuation > final Score
70
Valuation > verdict
100.0% Undervalued
Profitability > metrics > ROE
-34.013338564142806
Profitability > metrics > ROA
-26.051682692307693
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.4062377402903099
Risk > metrics > Interest Coverage
-0.34881291547958215
Risk > final Score
59
Risk > verdict
High
Liquidity > metrics > Current Ratio
11.770114942528735
Liquidity > metrics > Quick Ratio
11.770114942528735
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
90
Prev Valuations > 2
50
Prev Profitabilities > 0
15
Prev Profitabilities > 1
85
Prev Profitabilities > 2
55
Prev Risks > 0
-155
Prev Risks > 1
-609
Prev Risks > 2
-6115
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-16T12:50:24.923Z
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ASymphony Environmental Technologies (LON:SYM) Share Price Passes Below Two Hundred Day Moving Average – Should You Sell? Defense World
Read more →Highland nursery whistleblower awarded £400k after losing job over concerns about autistic boy’s treatment Northern Times
Read more →Showing 2 of 10
(Last Updated 2022-12-31)
Rating:
HOLD
Target Price:
$5
Analyst Picks
Strong Buy
0
Buy
0
Hold
1
Sell
0
Strong Sell
0
(Last Updated 2022-12-31)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.35% of the total shares of Calithera Biosciences Inc
1.
Vanguard US Opportunities Ins USD Acc(0.3222%)
since
2023/03/31
2.
FinTrust Capital Advisors, LLC(0.0246%)
since
2023/03/31
3.
JHVIT Total Stock Market Index I(0.0035%)
since
2023/04/30
4.
Bvf Inc(0%)
since
2023/03/31
5.
State Street Corporation(0%)
since
2023/03/31
6.
Acadian Asset Management LLC(0%)
since
2023/03/31
7.
Wells Fargo & Co(0%)
since
2023/03/31
8.
Tower Research Capital LLC(0%)
since
2022/12/31
9.
Citadel Advisors Llc(0%)
since
2023/03/31
10.
Morgan Stanley - Brokerage Accounts(0%)
since
2023/03/31
11.
BNP Paribas Arbitrage, SA(0%)
since
2022/12/31
12.
TSP Capital Management Group/LLC(0%)
since
2023/03/31
13.
Coppell Advisory Solutions LLC(0%)
since
2023/03/31
14.
Coppell Advisory Solutions Corp.(0%)
since
2023/03/31
15.
Arcus Capital Partners LLC(0%)
since
2023/03/31
16.
Citigroup Inc(0%)
since
2023/03/31
17.
UBS Group AG(0%)
since
2023/03/31
18.
Quent Capital, LLC(0%)
since
2023/03/31
19.
Renaissance Technologies Corp(0%)
since
2023/03/31
20.
Group One Trading, LP(0%)
since
2023/03/31
21.
PRIMECAP Management Company(0%)
since
2023/03/31
22.
Truvestments Capital LLC(0%)
since
2023/03/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2022-12-31)
(Last Updated 2022-12-31)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2022-12-31)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2022-12-31)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.